Confidentiality For Proprietary Information Drives FDA Plan To Generate More CBD Safety Data
In report to Congress about determining an enforcement discretion policy for CBD-containing non-drug products, FDA described challenges it faces, largely unique in its history, in determining whether hemp-derived ingredients are safe in food, supplements and other products that already are “sold increasingly widely."
You may also be interested in...
Study of 1,061 subjects showed oral CBD has robust safety profile, addressing FDA’s safety concerns and providing evidence to convince agency to take action on CBD regulation, say trade groups.
The FDA continues working to close cannabidiol data gaps while maintaining that CBD-containing cosmetics cannot be adulterated, misbranded or marketed as affecting body structure/function or treating or preventing disease, including skin ailments. Cosmetics office head Linda Katz revisited the issue during the Independent Beauty Association’s annual FDA Cosmetics Regulations Workshop.
Appropriations subcommittee notes the funding in summary of its draft budget bill. Language on FDA’s development of CBD regulatory framework will be included in panel’s report to be released 24 hours before full committee’s markup.